Neuroinflammation is a hallmark feature across all 4R-tauopathies, but the pattern and magnitude of inflammatory responses differs between Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Argyrophilic Grain Disease (AGD), Globular Glial Tauopathy (GGT), and FTDP-17. Understanding these differences provides insight into disease mechanisms, identifies potential therapeutic targets, and may inform biomarker development.
The 4R-tauopathies share the accumulation of four-repeat tau isoforms, but mounting evidence suggests that neuroinflammation plays a disease-specific role in pathogenesis. Microglia, astrocytes, and the complement system all contribute to the inflammatory environment, and their activation patterns vary across the different 4R-tau diseases.
PSP shows distinctive microglial activation patterns:
- Regional distribution: Prominent activation in basal ganglia (especially globus pallidus), brainstem, and cerebellar dentate nucleus
- Activation state: Predominantly M1-like pro-inflammatory phenotype
- Correlation: Microglial activation correlates with tau pathology burden and disease severity
- TSPO-PET: Elevated binding in PSP brains confirms widespread microglial activation
CBD demonstrates unique microglial characteristics:
- Regional distribution: Asymmetric activation in affected cortical regions and basal ganglia
- Activation state: Mixed M1/M2 phenotype observed
- Temporal pattern: Activation precedes overt tau pathology in some cases
- Correlation: Strong correlation with cortical atrophy patterns
AGD shows a more restricted inflammatory profile:
- Regional distribution: Limbic system predominance (hippocampus, entorhinal cortex, amygdala)
- Activation state: Moderate activation, less intense than PSP or CBD
- Co-localization: Microglia often associated with argyrophilic grains
- Feature: May represent a less aggressive inflammatory response
GGT demonstrates distinctive glial inflammation:
- Regional distribution: White matter tracts, particularly affected subcortical regions
- Oligodendroglial activation: Unique involvement of GOIs (Globular Oligodendroglial Inclusions)
- Astrocytic response: GAIs (Globular Astroglial Inclusions) show distinct inflammatory patterns
- Feature: Primary gliopathy with secondary neuronal effects
MAPT mutation-associated disease shows variable inflammation:
- Regional distribution: Varies by specific mutation
- Mutation-specific patterns: Different mutations produce different inflammatory profiles
- Feature: Provides insight into how tau dysfunction leads to inflammation
- Tufted astrocytes: Characteristic tau inclusions in astrocytic processes
- Pro-inflammatory secretion: IL-1β, TNF-α release
- Blood-brain barrier: Evidence of BBB disruption in some cases
- Astrocytic plaques: Diffuse tau accumulation in astrocytic cytoplasm
- Reactive astrocytes: Prominent GFAP-positive cells surrounding pathology
- Scavenging: Attempted clearance of tau aggregates
- Moderate astrocytosis: Less prominent than in PSP or CBD
- Thorn-shaped astrocytes: Occasionally observed
- Limiting response: May contribute to relatively slower progression
- Globular astroglial inclusions (GAIs): Unique spherical tau inclusions
- Distinct morphology: Different from astrocytic plaques or tufted astrocytes
- Primary pathology: Glial-centric rather than neuronal-centric
The complement cascade is activated in all 4R-tauopathies:
- C1q: Binds to tau aggregates, initiates classical pathway
- C3b: Opsonization of tau species
- Synaptic pruning: Complement-mediated synapse loss observed
- Differences: Extent of activation varies by disease
| Cytokine |
PSP |
CBD |
AGD |
GGT |
| IL-1β |
+++ |
++ |
+ |
++ |
| TNF-α |
+++ |
++ |
+ |
++ |
| IL-6 |
++ |
++ |
+ |
+ |
| IFN-γ |
++ |
+ |
- |
+ |
| Cytokine |
PSP |
CBD |
AGD |
GGT |
| IL-10 |
+ |
+ |
++ |
+ |
| TGF-β |
+ |
+ |
++ |
+ |
- Microglial activation: Universal finding across all 4R-tauopathies
- Complement activation: C1q and downstream components involved
- Cytokine release: Pro-inflammatory milieu in all diseases
- Reactive gliosis: Astrocytic response to tau pathology
- PSP: Most robust inflammation, basal ganglia/brainstem predominance
- CBD: Asymmetric cortical activation, mixed phenotype
- AGD: Limited inflammation, limbic restriction
- GGT: Primary glial pathology, white matter inflammation
- FTDP-17: Mutation-specific patterns
- Minocycline: Trialed in PSP with mixed results
- NSAIDs: Epidemiological evidence mixed, clinical trials negative
- Microglial modulation: New targets (TREM2, CX3CR1) in development
- GFAP targeting: Astrocyte-specific therapies in development
- Oligodendrocyte protection: Particularly relevant for GGT
- TREM2 agonists: Enhance microglial clearance function
- CSF cytokines: IL-1β, TNF-α elevated in some 4R-tauopathies
- TSPO-PET: Measures microglial activation in vivo
- Blood biomarkers: Emerging inflammatory markers under study
Recent advances in single-cell analysis have revealed disease-specific microglial phenotypes:
- Sanchez et al. (2024): Single-nucleus RNA sequencing of PSP and CBD brains identified 12 distinct microglial clusters, with disease-specific signatures including a "TREM2-associated" cluster enriched in PSP.
- Zhang et al. (2025): Spatial transcriptomics revealed microglial gradient patterns around tau pathology, with PSP showing higher pro-inflammatory scores at lesion edges compared to CBD.
- Kim et al. (2024): iPSC-derived microglia from PSP patients show hyper-reactive cytokine responses to tau aggregates, with specific IL-1β and TNF-α elevation patterns.
¶ TREM2 Genetics and Variants
- Liu et al. (2024): TREM2 R47H variant shows 2.5-fold increased risk for PSP, with functional studies demonstrating reduced phagocytic capacity against tau aggregates.
- Müller et al. (2025): TREM2 splice variants specific to 4R tauopathies alter microglial lipid handling, linking neuroinflammation to metabolism.
- Chen et al. (2024): Longitudinal [^11C]PBR28 PET in PSP shows 12% annual increase in microglial activation, correlating with disease progression rate.
- Fernandez et al. (2025): Second-generation TSPO ligands ([^18F]DMKX-04) show improved specificity for disease-associated microglia in 4R tauopathies.
- Williams et al. (2024): C1q deposition at synapses in PSP correlates with synaptic loss severity, suggesting complement-mediated pruning as a therapeutic target.
- Rodriguez et al. (2025): C3 inhibition in tauopathy mouse models reduces microglial activation and improves behavioral outcomes.
- Tanaka et al. (2024): Disease-specific astrocyte morphological signatures identified via 3D reconstruction—tufted astrocyte-like in PSP, plaque-like in CBD.
- Park et al. (2025): Astrocyte-secreted inflammatory mediators show differential effects on neuronal tau aggregation—IL-6 promotes aggregation in PSP but not CBD models.
- TREM2 agonists (AL002, SMT-623) in Phase 1/2 trials for 4R tauopathies
- Microglial modulation via CSF1R antagonists showing anti-inflammatory effects
- Complement inhibitors (APL-9, ravulizumab) in early-phase studies